Mural Oncology (MURA) Competitors $2.76 -0.22 (-7.38%) Closing price 04:00 PM EasternExtended Trading$2.68 -0.08 (-3.04%) As of 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MURA vs. PRME, INMB, VYGR, MOLN, ELDN, OGI, INBX, PRQR, HURA, and DMACShould you be buying Mural Oncology stock or one of its competitors? The main competitors of Mural Oncology include Prime Medicine (PRME), INmune Bio (INMB), Voyager Therapeutics (VYGR), Molecular Partners (MOLN), Eledon Pharmaceuticals (ELDN), Organigram (OGI), Inhibrx (INBX), ProQR Therapeutics (PRQR), TuHURA Biosciences (HURA), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry. Mural Oncology vs. Prime Medicine INmune Bio Voyager Therapeutics Molecular Partners Eledon Pharmaceuticals Organigram Inhibrx ProQR Therapeutics TuHURA Biosciences DiaMedica Therapeutics Prime Medicine (NYSE:PRME) and Mural Oncology (NASDAQ:MURA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability, community ranking and analyst recommendations. Which has stronger valuation and earnings, PRME or MURA? Prime Medicine has higher revenue and earnings than Mural Oncology. Prime Medicine is trading at a lower price-to-earnings ratio than Mural Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrime Medicine$3.85M38.41-$198.13M-$1.61-0.70Mural OncologyN/AN/A-$207.45M-$7.67-0.36 Do analysts rate PRME or MURA? Prime Medicine currently has a consensus price target of $11.80, suggesting a potential upside of 948.89%. Mural Oncology has a consensus price target of $13.00, suggesting a potential upside of 367.63%. Given Prime Medicine's stronger consensus rating and higher probable upside, equities research analysts plainly believe Prime Medicine is more favorable than Mural Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prime Medicine 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86Mural Oncology 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Does the media prefer PRME or MURA? In the previous week, Prime Medicine had 14 more articles in the media than Mural Oncology. MarketBeat recorded 17 mentions for Prime Medicine and 3 mentions for Mural Oncology. Mural Oncology's average media sentiment score of 1.00 beat Prime Medicine's score of 0.07 indicating that Mural Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Mural Oncology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, PRME or MURA? Prime Medicine has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500. Comparatively, Mural Oncology has a beta of 3.91, suggesting that its stock price is 291% more volatile than the S&P 500. Does the MarketBeat Community prefer PRME or MURA? Prime Medicine received 22 more outperform votes than Mural Oncology when rated by MarketBeat users. However, 80.00% of users gave Mural Oncology an outperform vote while only 65.22% of users gave Prime Medicine an outperform vote. CompanyUnderperformOutperformPrime MedicineOutperform Votes3065.22% Underperform Votes1634.78% Mural OncologyOutperform Votes880.00% Underperform Votes220.00% Do institutionals and insiders believe in PRME or MURA? 70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 80.2% of Mural Oncology shares are held by institutional investors. 23.5% of Prime Medicine shares are held by insiders. Comparatively, 0.1% of Mural Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is PRME or MURA more profitable? Mural Oncology's return on equity of -70.10% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Prime MedicineN/A -107.87% -74.97% Mural Oncology N/A -70.10%-61.30% SummaryPrime Medicine beats Mural Oncology on 10 of the 17 factors compared between the two stocks. Get Mural Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for MURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MURA vs. The Competition Export to ExcelMetricMural OncologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.01M$6.51B$5.38B$8.42BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-0.308.9726.6219.77Price / SalesN/A253.27392.02116.56Price / CashN/A65.8538.2534.62Price / Book0.186.486.814.53Net Income-$207.45M$143.98M$3.23B$248.18M7 Day Performance8.59%3.37%4.05%1.06%1 Month Performance3.35%7.83%11.64%14.68%1 Year Performance-26.26%-2.24%17.11%6.87% Mural Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MURAMural Oncology2.322 of 5 stars$2.76-7.4%$13.00+371.0%-21.0%$47.66MN/A-0.30119Earnings ReportPRMEPrime Medicine3.7023 of 5 stars$1.34+3.1%$12.83+857.7%-84.4%$175.76M$3.85M-0.65234Trending NewsAnalyst ForecastAnalyst RevisionGap DownINMBINmune Bio1.9353 of 5 stars$7.64+9.6%$22.80+198.4%-31.6%$175.60M$14,000.00-3.5010Positive NewsGap DownVYGRVoyager Therapeutics4.6568 of 5 stars$3.35+5.7%$13.97+316.9%-59.8%$175.42M$66.96M4.72100Gap UpMOLNMolecular Partners1.9518 of 5 stars$4.28+4.4%$12.00+180.4%+5.6%$172.81M$4.97M-1.99180News CoverageEarnings ReportAnalyst RevisionGap UpELDNEledon Pharmaceuticals2.1568 of 5 stars$2.87-0.7%$12.50+335.5%-1.9%$171.86MN/A-1.4310News CoveragePositive NewsEarnings ReportAnalyst RevisionGap UpOGIOrganigram0.2552 of 5 stars$1.28+8.5%N/A-32.2%$171.31M$166.12M-3.37860Gap DownHigh Trading VolumeINBXInhibrx1.8879 of 5 stars$11.71+4.7%N/A-62.1%$169.51M$200,000.000.00166Earnings ReportPRQRProQR Therapeutics3.1895 of 5 stars$1.59-1.2%$8.75+450.3%-8.3%$167.29M$18.91M-4.97180HURATuHURA BiosciencesN/A$3.82-4.3%$12.67+231.6%N/A$166.86MN/A0.00N/ANews CoverageEarnings ReportAnalyst RevisionDMACDiaMedica Therapeutics1.4905 of 5 stars$3.83+4.6%$8.00+108.9%+35.3%$163.92MN/A-6.8420News CoverageAnalyst RevisionGap Up Related Companies and Tools Related Companies Prime Medicine Competitors INmune Bio Competitors Voyager Therapeutics Competitors Molecular Partners Competitors Eledon Pharmaceuticals Competitors Organigram Competitors Inhibrx Competitors ProQR Therapeutics Competitors TuHURA Biosciences Competitors DiaMedica Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MURA) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mural Oncology plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Mural Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MURA Stock Free MURA Stock Alerts